Are you a Health Professional? Jump over to the doctors only platform. Click Here

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Print Friendly, PDF & Email

The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.

Official Title

A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus


Obesity, Type 2 Diabetes Mellitus

Study Type


Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further Details

  • Primary Outcome Measures: Change in body weight over one year.
  • Secondary Outcome Measures: HbA1c, BP, blood lipids, fasting glucose, waist circumference, quality of life over 1 year.

Study Start

November 2006

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years – 70 Years
  • Genders Eligible for Study: Both

Inclusion Criteria:

  • Subjects must be overweight (BMI 27-45 kg/m2).
  • Subjects must have type 2 diabetes mellitus

Exclusion Criteria:

  • Pregnancy
  • Serious or unstable current or past medical conditions

Total Enrolment


Contact Details

Australian Locations:

  • Pfizer Investigational Site, Garran, Australian Capital Territory, Australia; Recruiting
  • Pfizer Investigational Site, Wollongong, New South Wales, Australia; Recruiting
  • Pfizer Investigational Site, Adelaide, South Australia, Australia; Recruiting
  • Pfizer Investigational Site, Box Hill, Victoria, Australia; Recruiting
  • Pfizer Investigational Site, Nedlands, Western Australia, Australia; Recruiting

Contact Pfizer for more information about this trial.

Print Friendly, PDF & Email


Posted On: 1 January, 2013
Modified On: 21 January, 2014


Created by: myVMC